StockData
HCW Biologics Inc. logo

HCW Biologics Inc. (HCWB) stock

HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)

Close on Nov 18, 2026Market cap $1.40MP/E –Yield –

HCW Biologics operating margin

Operating margin is operating income as a percentage of revenue.

HCW Biologics's operating margin for the twelve months ending Jun 30, 2026 was -115.3%. For fiscal 2025 it was -24270.7%, against -1147.6% the year before. The highest annual figure on record is -142.1% in fiscal 2020.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-24270.7%−23123.1
FY2024Dec 31, 2024-1147.6%−242.6
FY2023Dec 31, 2023-905.0%−680.6
FY2022Dec 31, 2022-224.3%−82.2
FY2020Dec 31, 2020-142.1%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-2601.1%+50285.6
Q1 FY2026Mar 31, 202649.8%+38861.3
Q4 FY2025Dec 31, 2025-16519.1%−15721.9
Q3 FY2025Sep 30, 2025-21095.3%−20231.2
Q2 FY2025Jun 30, 2025-52886.7%−50440.9
Q1 FY2025Mar 31, 2025-38811.5%−38146.4
Q4 FY2024Dec 31, 2024-797.2%+16.1
Q3 FY2024Sep 30, 2024-864.1%−268.8
Q2 FY2024Jun 30, 2024-2445.8%−1721.6
Q1 FY2024Mar 31, 2024-665.1%+12133.8
Q4 FY2023Dec 31, 2023-813.3%−390.9
Q3 FY2023Sep 30, 2023-595.2%−373.0
Q2 FY2023Jun 30, 2023-724.2%+49.1
Q1 FY2023Mar 31, 2023-12798.9%−12738.6
Q4 FY2022Dec 31, 2022-422.4%−472.7
Q3 FY2022Sep 30, 2022-222.2%–
Q2 FY2022Jun 30, 2022-773.4%–
Q1 FY2022Mar 31, 2022-60.3%–
Q4 FY2020Dec 31, 202050.3%–

More HCW Biologics figures

See a number that looks wrong?